外周动脉疾病的药物与生活方式管理
本文综述了外周动脉疾病(PAD)非侵入性管理的证据,涵盖戒烟、运动疗法、抗血小板、抗凝、降压、降脂及糖尿病血糖控制,并据此给出临床推荐。结论认为药物与生活方式管理应旨在改善功能结局并减少主要不良心血管事件(MACE),推荐多因素综合干预。
要点
- 尼古丁替代、安非他酮和伐尼克兰安全且比安慰剂更有效实现戒烟。
- 监督下运动疗法是间歇性跛行的理想治疗;步数监测运动可提高步行表现和依从性。
- 氯吡格雷优于单用阿司匹林;低剂量利伐沙班加阿司匹林减少MACE且不显著增加大出血。
核心结论
- PAD的药物与生活方式管理应旨在改善功能结局并减少MACE。
- 推荐戒烟咨询或药物治疗,但需要新策略。
- 监督下运动疗法是理想选择,但临床实施可能存在障碍。
- 推荐多因素综合干预以改变该疾病的自然史。
- 需要更多研究探讨强化血糖、血压和血脂控制在PAD患者中的作用。
研究设计与样本
- 本文为综述,进行了全面文献回顾,以检查戒烟、运动疗法、抗血小板治疗、抗凝治疗、抗高血压治疗、降脂治疗和糖尿病血糖控制对PAD患者的证据。
主要发现
- 尼古丁替代、安非他酮和伐尼克兰安全且比安慰剂更有效实现戒烟。
- 监督下运动疗法是间歇性跛行的理想治疗;步数监测运动可在较少人员监督下增加步行表现和参与者依从性。
- 氯吡格雷对所有患者优于单用阿司匹林;小型研究支持血运重建后使用双联抗血小板治疗以改善肢体结局。
- 低剂量利伐沙班加用阿司匹林被证明在减少MACE方面更有效,且不显著增加大出血;直接口服抗凝治疗在PAD管理中的确切作用仍在认识中。
- 有证据显示比传统目标更强化的血压和降脂治疗;糖尿病管理仍具挑战,因血糖控制尚未被证明改善大血管结局,血糖控制对微血管疾病的潜在影响需与低血糖风险权衡;钠-葡萄糖协同转运蛋白2抑制剂似乎减少MACE,但鉴于卡格列净临床试验中下肢截肢发生率增加,建议谨慎。
关键数值与推荐
- 尼古丁替代、安非他酮和伐尼克兰安全且比安慰剂更有效实现戒烟。
- 监督下运动疗法是间歇性跛行的理想治疗;步数监测运动可作为替代以增加步行表现和依从性。
- 氯吡格雷对所有患者优于单用阿司匹林;小型研究支持血运重建后双联抗血小板治疗以改善肢体结局。
- 低剂量利伐沙班加用阿司匹林在减少MACE方面更有效且不显著增加大出血。
- 钠-葡萄糖协同转运蛋白2抑制剂似乎减少MACE,但鉴于卡格列净临床试验中下肢截肢发生率增加,建议谨慎。
临床怎么用
- 推荐戒烟咨询或药物治疗。
- 监督下运动疗法为理想治疗,步数监测运动可作为替代。
- 氯吡格雷对所有患者优于单用阿司匹林。
- 低剂量利伐沙班加用阿司匹林可减少MACE且不显著增加大出血。
- 推荐多因素综合干预以改变疾病自然史。
局限性
- PAD研究有限。
- 需要更多研究探讨强化血糖、血压和血脂控制在PAD患者中的作用。
- 需要新策略以实现戒烟。
- 监督下运动疗法在临床实施中可能存在障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Peripheral arterial disease (PAD) is a global health issue associated with impaired functional capacity and elevated risk of major adverse cardiovascular events (MACEs). With changing risk factor profiles and an aging population, the burden of disease is expected to increase. This review considers evidence for the noninvasive management of PAD and makes clinical recommendations accordingly. METHODS: A comprehensive literature review was performed to examine the evidence for smoking cessation, exercise therapy, antiplatelet therapy, anticoagulant therapy, antihypertensive therapy, lipid-lowering therapy, and glycemic control in diabetes for patients with PAD. RESULTS: Nicotine replacement, bupropion, and varenicline are safe and more effective than placebo in achieving smoking abstinence. Wherever it is practical and available, supervised exercise therapy is ideal treatment for intermittent claudication. Alternatively, step-monitored exercise can increase walking performance and the participant's compliance with less staff supervision. Clopidogrel is preferable to aspirin alone for all patients. However, small studies support the use of dual antiplatelet therapy after revascularization to improve limb outcomes. More recently, the addition of low-dose rivaroxaban to aspirin alone was proven to be more effective in reducing MACEs without a significant increase in major bleeding. However, the exact role of direct oral anticoagulant therapy in the management of PAD is still being understood. Evidence is emerging for more intensive blood pressure and lipid-lowering therapy than traditional targets. Whereas research in PAD is limited, there is clinical scope for an individualized approach to these risk factors. The management of diabetes remains challenging as glycemic control has not been demonstrated to improve macrovascular outcomes. Any potential impact of glycemic control on microvascular disease needs to be weighed against the risks of hypoglycemia. Sodium-glucose cotransporter 2 inhibitors appear to reduce MACEs, although caution is advised, given the increased incidence of lower limb amputation in clinical trials of canagliflozin. CONCLUSIONS: Medical and lifestyle management of PAD should aim to improve functional outcomes and to reduce MACEs. Smoking cessation counseling or pharmacotherapy is recommended, although new strategies are needed. Whereas supervised exercise therapy is ideal, there can be barriers to clinical implementation. Other initiatives are being used as an alternative to walking-based supervised exercise therapy. More studies are required to investigate the role of intensive glycemic, blood pressure, and dyslipidemia control in patients with PAD. Overall, a multifactorial approach is recommended to alter the natural history of this condition.
引用
- Parvar SL, Fitridge R, Dawson J, et al. Medical and lifestyle management of peripheral arterial disease. J Vasc Surg. 2018. PMID: 30360849. doi:10.1016/j.jvs.2018.07.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。